INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 428m ago
HOUSE PTR28m ago
SEC 13F28m ago
ROBINHOOD CHAIN28m ago
SEC FORM 4/Tax withholdingVerified data

Tupper Colleen reported COLL

EVP & Chief Financial Officer · COLLEGIUM PHARMACEUTICAL, INC · Common Stock

Side
F
Value
$1.25M
Shares
26.7K
Price
$46.75
Executed
Feb 10, 2026
Disclosed
Feb 12, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 10 executedFeb 12, 2026 disclosed

COLL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
22/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+18 / 25

$1.2M reported value · 22.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · COLL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GM
    Glancy Donovan MichaelDirector
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    17.5K sh
    		May 14, 2026May 18, 2026
    traded May 14, 2026
    		+4dSEC FORM 4

    Evidence

    25
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$316K
    8,840 sh
    		Mar 17, 2026Apr 3, 2026
    traded Mar 17, 2026
    		+17dSEC FORM 4

    Evidence

    11
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$488K
    14.0K sh
    		Mar 18, 2026Mar 20, 2026
    traded Mar 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$228K
    6,224 sh
    		Mar 9, 2026Mar 11, 2026
    traded Mar 9, 2026
    		+2dSEC FORM 4

    Evidence

    15
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$555K
    11.9K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    17
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    22.2K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    13
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    9,005 sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    12
    DD
    Dieter DavidEVP & General Counsel
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$130K
    2,781 sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    26.4K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    13
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Grant or award
    		A—
    32.7K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    20
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$315K
    6,475 sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    20
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$533K
    11.1K sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Option exercise · 10b5-1 plan
    		M$280K
    17.6K sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    0
    DS
    Dreyer ScottEVP & Chief Commercial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Option exercise · 10b5-1 plan
    		M—
    17.6K sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    33
    BJ
    Balice-Gordon Rita J.Director
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale
    		SELL$172K
    3,650 sh
    		Dec 5, 2025Dec 9, 2025
    traded Dec 5, 2025
    		+4dSEC FORM 4

    Evidence

    19
    KV
    Karnani VikramDirector, President and CEO
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Tax withholding
    		F$425K
    8,983 sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    18
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$1.02M
    25.1K sh
    		Nov 6, 2025Nov 7, 2025
    traded Nov 6, 2025
    		+1dSEC FORM 4

    Evidence

    8
    TC
    Tupper ColleenEVP & Chief Financial Officer
    COLLCOLLEGIUM PHARMACEUTICAL, INC
    Open-market sale · 10b5-1 plan
    		SELL$201K
    4,858 sh
    		Nov 6, 2025Nov 7, 2025
    traded Nov 6, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001862082-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 10, 2026
    Published
    Feb 12, 2026
    Ingested by INSIDER
    Nov 5, 04:17 UTC
    Last re-read
    Nov 5, 04:17 UTC

    Extracted facts

    Filer
    Tupper Colleen
    Role
    EVP & Chief Financial Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    COLLEGIUM PHARMACEUTICAL, INC
    Ticker
    COLL
    Shares
    26.7K
    Price per share
    $46.75
    Value
    $1,247,243
    Execution date (reported)
    Feb 10, 2026
    Owned after transaction
    147.3K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 26.7K
    • Price: $46.75

    = $1,247,243

    What this establishes

    Tupper Colleen filed this Form 4 reporting a tax withholding of COLL on Feb 10, 2026. It became public on Feb 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP & Chief Financial Officer
    Tupper Colleencik:0001862082
    Issuer
    COLLEGIUM PHARMACEUTICAL, INCcik:0001267565

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.